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Abstract (unstructured) 
The development of core outcome sets (COS), i.e. a minimum set of ‘core outcomes’ that should 
be measured and reported in all trials or clinical practice of a specific condition, in dermatology is 
gathering pace. A total of 44 dermatology-related COS projects have been registered in the 
online Core Outcome Measures in Effectiveness Trials (COMET) database 
(http://www.comet-initiative.org/studies/search), and include studies on 26 different skin 
diseases. With the increasing number of COS in dermatology, care is needed to ensure the 
delivery of high quality COS that meet quality standards based on state of the art 
methodology. In 2015, the Cochrane Skin – Core Outcome Set Initiative (CS-COUSIN) was 
established. CS-COUSIN is an international, multidisciplinary working group, aiming to 
improve the development and implementation of COS in dermatology. CS-COUSIN has 
developed guidance on how to develop high quality COS for skin diseases, and supports 
dermatology-specific COS initiatives. Currently, 16 COS development groups are affiliated to 
CS-COUSIN following standardized COS development processes. To ensure successful uptake 
of COS in dermatology, researchers, clinicians, systematic reviewers, guideline developers 
and other stakeholders should use existing COS in their work. 
 
Capsule summary 
• Core outcome set development must follow state-of-the-art methodology.  
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• CS-COUSIN provides methodological support for dermatology-specific core outcome 
set initiatives to ensure high quality across core outcome sets in dermatology.  
 
Key words:  
Dermatology, Cochrane Skin, CS-COUSIN, clinical trials, core outcome set, development, 
implementation 
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Introduction 
For most skin diseases or conditions, it is unclear what aspects need to be measured in 
clinical trials so that patients, healthcare professionals and commissioners can make fully 
informed decisions about treatment options. Even when it is clear what needs to be 
measured as a clinical trial outcome, the outcome measurement instruments available may 
be deficient in terms of validity, reliability and feasibility - or just completely absent. Such a 
knowledge vacuum results in a chaotic non-uniformity of outcome reporting in dermatology 
clinical trials, which at best limits, and at worst prevents, meaningful meta-analysis and 
interpretation of trial evidence. It may lead to selective outcome reporting; hinders 
comparison of healthcare effects within and across healthcare organisations, and 
benchmarking of healthcare quality;
1-7
 and hampers informed healthcare decision making.
1
 
Continuation of clinical trials without a focus on their comparability fails to progress 
evidence-based medicine and is considered a serious waste in research.
8-12
 Clinical trials can 
no longer be thought of as a means to an end as most now typically have a “second life” in 
the form of systematic reviews that combine all relevant evidence such as those conducted 
by Cochrane Skin.
13
 
 
Thankfully, a solution has been found in the form of Core Outcome Sets (COS) as a means of 
standardizing outcome measurement and reporting in clinical trials. A COS is a minimum set 
of the most important outcomes that should be measured and reported in all clinical trials 
for a specific health condition
14
, including definitions and the core outcome measurement 
instruments or methods used to measure the core outcomes. A core outcome does not have 
to be the primary outcome of a clinical trial and, as such, the COS can be measured in 
addition to other outcomes of interest. Although the primary emphasis of a COS is for clinical 
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trials, they can also be used in routine clinical care, for clinical registries, for defining 
important outcomes in systematic reviews, or for funders of research to ensure that they are 
funding research that is measuring important aspects of the disease from the perspective of 
patients and healthcare professionals.  
COS hold great potential to improve rigor and relevance of clinical research but to make this 
potential true, the COS itself need to be developed in a rigorous manner. Reference 
standards are therefore required for preferred methods of COS development, both across 
disciplines and within a single discipline to account for subject-specific methodological 
challenges. The purpose of this article is to navigate through the landscape of COS 
development in medicine and, more specifically, in the field of dermatology.  
 
Early pioneers of outcome standardization in medicine 
One of the first attempts to standardize outcomes in clinical trials was the World Health 
Organization (WHO)
15
 in 1981, when Miller and colleagues published recommendations for 
standardized approaches to recording data for cancer patients. Since then, interest in 
standardization of outcomes research has grown and international initiatives on COS 
development have been launched in many medical disciplines. Since 1992, the Outcome 
Measures in Rheumatology initiative (OMERACT, http://www.omeract.org) has been the 
frontrunner in COS development in medicine. The uptake of the COS in rheumatoid arthritis 
clinical trials increased from 40% in 1995 to 81% in 2016.
16
  Furthermore, the rheumatoid 
arthritis COS is now required by the U.S. Food and Drug Administration (FDA) to be 
measured in clinical trials in RA.
17
  These trials are now more comparable, enabling meta-
analysis of clinical trial data and improved health outcomes for patients.
16
 The development 
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of COS in healthcare research has rapidly grown over recent years with 299 published COS 
up to 2017.
18,19
  
 
Developing standards for Core Outcome Set development 
Two main organisations have emerged as leaders in the development of COS globally. The 
Core Outcome Measures in Effectiveness Trials-Initiative (COMET, 
http://www.cometinitiative.org) was established in 2010 and is an international umbrella 
organization that supports the development, dissemination and implementation of COS by 
establishing agreed COS development methodologies.
20-23
 COS development typically implies 
a range of methodological techniques to identify all possible outcomes by means of 
systematic reviews and qualitative methods. Subsequently, consensus should be reached on 
the most important outcome domains and outcome measurement instruments. This may 
include international e-Delphi consensus studies; face-to-face consensus meetings, including 
small and large groups discussions; presentations of evidence; and anonymised voting. 
Furthermore, COMET maintains an international database for existing and ongoing work on 
COS development in healthcare that helps to reduce duplication of effort.
24
 To date, the 
focus of COMET has been to encourage groups to identify the most important outcome 
domains for clinical trials. Outcome domains can be thought of as the key aspects of a 
disease that are needed to evaluate the effectiveness of an intervention.
20
 Examples of 
outcome domains include pain intensity, physical functioning, or fatigue.  
 
By contrast, the COnsensus-based Standards for the selection of health Measurement 
INstruments (COSMIN, www.cosmin.nl) initiative focusses on the selection of outcome 
measurement instruments to measure the important outcome domains in the COS. To 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
  
improve the selection of outcome measurement instruments, COSMIN has developed 
guidance on how to select instruments for outcomes included in a COS.
20
 In four consecutive 
steps, COS developers are being guided through the process of outcome measurement 
instrument selection for COS, including finding existing instruments by means of literature 
searches and/or systematic reviews, and quality assessment of existing instruments (i.e. 
evaluation of the measurement properties and feasibility aspects). Furthermore, COSMIN 
has developed guidance on systematic reviews of patient-reported outcome measurement 
instruments
25
, and guidance on the evaluation of the methodological quality of studies on 
the measurement properties of outcome measurement instruments.
26,27
 The COSMIN 
methodology can be used to inform the selection of the most suitable outcome 
measurement instruments to measure the core outcome domains. 
 
In addition to COS development, the International Consortium for Health Outcomes 
Measurement (ICHOM, http://www.ichom.org/), founded in 2012, aims to improve value-
based healthcare by developing Standard Sets. Standard Sets are similar to COS but with a 
clear focus on clinical practice. To date, ICHOM has developed 24 Standard Sets for some of 
the most prevalent diseases and for vulnerable populations (e.g. cardiovascular, 
neurological, oncological and musculoskeletal disease areas)
28
, but none of these are 
currently dermatology-specific.  
 
Core outcome set development in dermatology  
The longest running COS initiative in dermatology is the Harmonising Outcome Measures for 
Eczema (HOME) initiative. Founded in 2008, HOME is a global initiative of patients, 
healthcare professionals, journal editors, regulatory authorities and the pharmaceutical 
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industry, with a mission to harmonize outcome measurement and reporting in atopic 
eczema clinical trials and clinical practice. In-depth research on outcomes and measurement 
instruments, followed by a series of successful consensus meetings, resulted in a 
recommendation on four core outcome domains to be measured in all atopic eczema clinical 
trials: signs, symptoms, long-term control, and quality of life
29
. EASI and POEM are the 
recommended outcome measurement instruments to measures signs and symptoms 
respectively.
30-32
 The HOME group has published a methodological roadmap outlining the 
essential steps in the development of and implementation of COS in dermatology.
33
   
 
With so many different dermatoses, the need for standardization in outcome reporting in 
dermatology is imperative.
34
 In 2015, the Cochrane Skin – Core Outcome Set Initiative (CS-
COUSIN, www.cs-cousin.org) was established. CS-COUSIN is an international, 
multidisciplinary working group, aiming to improve the development and implementation of 
COS in dermatology. CS-COUSIN is an umbrella organization to support dermatology-specific 
initiatives to develop their COS. Recently, the CS-COUSIN methods group has conducted a 
systematic review to assess the concordance between efficacy outcomes in a random 
sample of 10 Cochrane Skin systematic reviews and the 220 dermatology clinical trials that 
are included in these reviews.
35
 Results show a low concordance of outcomes between 
reviews and primary studies, and it was concluded that standardization of outcome 
reporting could be improved by the development and implementation of COS.   
Fortunately, and since the inauguration of HOME in 2008, the development of COS in 
dermatology is gathering pace. A total of 44 dermatology-related COS projects have been 
registered in the COMET database,
24
 and include studies on 26 different skin diseases, such 
as acne, AE, hidradenitis suppurativa, melanoma, nail psoriasis, rosacea, and vitiligo
24
 (Table 
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1). Most COS are being developed for research and/or clinical practice purposes; two 
registered COS-related projects are focussing on the development of a “core set of domains 
and domain items” for registry purposes, i.e. the TREatment of ATopic eczema (TREAT) 
initiative
36,37
 and the European Laser TrEAtment Dermatology (LEAD) Registry.
24
  
To achieve a similar level of success in dermatology as OMERACT has achieved in 
rheumatology
16
, care is needed to ensure the delivery of high quality COS that meet quality 
standards based on state of the art methodology.
20,21,23,25,33,38,39
 Based on the HOME 
roadmap, the CS-COUSIN methods group has developed guidance on how to develop COS 
for skin disease
40
, including a flow diagram for the domain development process and one for 
the  outcome measurement instrument selection/development process (Figures 1 and 2).  
An important difference between CS-COUSIN and COMET is that CS-COUSIN provides direct 
methodological support for skin-related COS and is embedded within the international 
Cochrane Skin group, thus ensuring speedy adoption of COS within high quality systematic 
reviews that are used by guideline developers.  
To date, 16 COS initiatives have been supported by CS-COUSIN.
41
 To ensure high 
quality across COS in dermatology, groups developing COS are supplied with access to 
protocol templates and recommendations on best practice, and all are assigned a COUSIN 
Methods Group representative who provides support for the individual groups as a ‘critical 
friend’. In addition, CS-COUSIN organises annual meetings whereby knowledge, ideas, and 
issues with regard to COS development are exchanged and debated amongst CS-COUSIN 
members and external experts from COMET, COSMIN and OMERACT.
5,42
 An overview of COS 
projects supported by CS-COUSIN is provided in Table 2, and detailed information about 
these COS projects can be found on the CS-COUSIN website.
41
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Another initiative in dermatology, although not affiliated within COMET or CS-COUSIN, is the 
International Dermatology Outcome Measures (IDEOM, http://dermoutcomes.org/). IDEOM 
seeks to develop and validate dermatology outcome measurement instruments throughout 
dermatology with an initial focus on psoriatic disease.
43
  
 
[Table 2 about here] 
 
It is important to ensure and to increase international cooperation and collaboration 
between different COS initiatives in dermatology. It is therefore recommended that present 
and future COS projects are embedded within CS-COUSIN, to ensure quality standards for 
COS development. The embedding of COS projects within CS-COUSIN facilitates the 
exchange of cutting edge knowledge in an international community of COS developers and 
methodologists that supports COS development and uptake on a global level. CS-COUSIN is 
open for everyone with an interest in outcomes research and evidence-based dermatology 
and with enthusiasm to develop and implement COS in dermatology. 
 
CS-COUSIN encourages COS developers to have a clear focus on patient-centeredness and 
embraces the importance of the involvement of patient research partners in steering 
committees and throughout the entire course of the COS development process. 
Standardization of patient-centred outcome reporting allows for synthesizing clinical trial 
results in a meaningful way. This significantly impacts the patient-value of evidence from 
research and clinical practice, and allows for delivering value-based health care.
44
 
Future directions of COS development might include innovative new generic outcome 
measurement instruments based on Item Response Theory and Computerized Adaptive 
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Testing (a computer-based test system). These new outcome measurement instruments 
have recently become available and measure aspects of health more precisely and in a more 
tailored way than traditional outcome measurement instruments that are based on Classical 
Test Theory.
45-48
 HOME, for example, is currently exploring the possibilities of the 
implementation of Patient-Reported Outcomes Measurement Information System (PROMIS)  
instruments in the COS for atopic eczema. In addition to research, the possibility to use COS 
for the evaluation of dermatological clinical practice should be also developed further. 
 
The challenge to uptake of COS 
Global uptake of a COS is crucial to overcome the problem of non-uniformity in outcome 
reporting. One way of ensuring early adoption into clinical trials is to ensure early 
engagement with regulatory agencies such as the FDA and European Medicines Agency 
(EMA). To ensure a successful uptake of the various COS in dermatology, it is important that 
researchers, clinicians, systematic reviewers and other stakeholders adhere to the COS in 
their own research work. In doing so, they can be reassured that they are measuring 
important aspects of the disease in the most reliable, valid and responsive way, and are 
contributing to a reduction in research waste and improved patient care.
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Figure legend 
Figure 1. CS-COUSIN flow diagram for the domain development process 
Figure 2. CS-COUSIN flow diagram for the outcome measurement instrument 
selection/development process 
 
 
Table legend 
Table 1. Overview of COS-related projects in dermatology, registered in the COMET database 
Table 2. Overview of COS projects supported by CS-COUSIN 
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Table 1. Overview of COS-related projects in dermatology, registered in the COMET 
database
24
 
 
 Skin diseases 
Number 
of 
projects 
COS for 
clinical 
research 
COS for 
clinical 
practice 
COS for 
registry 
Other 
1 Acne Vulgaris
*
 1 X    
2 Acne Scarring  1 X X   
3 Actinic keratosis  1 X X   
4 Atopic eczema
*
  11 X X X 
Systematic reviews, 
meeting reports, 
consensus reports, 
recommendations, 
guideline 
5 
Basal Cell 
Carcinoma
*
  
1 X X   
6 
Congenital 
melanocytic naevi 
1 X X   
7 
Cutaneous 
leishmaniasis   
2 X X   
8 
Epidermolysis 
bullosa 
1 X X   
9 Facial aging
*
  1 X X   
10 
Facial Structure and 
Function Post-Skin 
Cancer Excision  
1 X X   
11 
Hair Loss/non-
scarring alopecia  
1 X X   
12 
Head and neck 
lymphatic 
malformation  
1 X    
13 
Hidradenitis 
Suppurativa
*
  
1 X    
14 Hyperhidrosis  1 X X   
15 
Incontinence-
associated 
dermatitis
*
  
1 X    
16 Leprosy  1 - -  Overview of literature 
17 Melanoma
*
  1 X    
18 Melasma  1 X X   
19 Nail psoriasis
*
  2 X   
Systematic review, 
overview of literature 
20 
Post Inflammatory 
Hyperpigmentation  
1 X X   
21 Pressure Ulcer
*
 1 X    
22 Rosacea
*
  1 X X   
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23 Scarring  1 X X   
24 
Squamous Cell 
Carcinoma  
1 X X   
25 
Vascular 
Malformations 
1 X   
Systematic review and 
consensus report  
26 
Vasculitis (small-
vessel/ ANCA-
associated) 
1 X    
27 Vitiligo
*
  4 X   
Systematic review, 
consensus report, 
recommendations, 
guideline 
28 
Vulval skin 
disorders  
1 X X  Systematic review 
29 
Medical Indications 
for Laser 
Treatments in 
Dermatology
*
 
1 X X X  
TOTAL 44  
*
 Supported by CS-COUSIN 
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Table 2. Overview of COS projects supported by CS-COUSIN 
 
 Skin disease COS initiative Acronym 
1 Acne Vulgaris Acne Core Outcomes Research Network ACORN 
2 Atopic eczema Harmonising Outcome Measures for Eczema  HOME 
3 
Basal Cell 
Carcinoma (BCC) 
Core outcome set for clinical trials in Basal Cell 
Carcinoma 
IMPROVED 
4 
Chronic 
spontaneous 
urticaria (CSU) 
Core Outcome Measures in Chronic 
Spontaneous Urticaria 
- 
5 Chronic Wounds 
Developing a Core Outcome Set for Chronic 
Wounds 
- 
6 Facial aging 
Core Outcome Set for the Appearance of Facial 
Aging 
IMPROVED 
7 Hand eczema 
Development of a Hand Eczema Core Outcome 
Set 
HECOS 
8 
Hidradenitis 
Suppurativa 
Development of a Core Outcome Set in 
Hidradenitis Suppurativa 
HISTORIC 
9 
Incontinence-
Associated 
Dermatitis 
Core Outcome Set in IAD Research project: 
development of a core set of outcomes and 
measurement instruments for Incontinence-
Associated Dermatitis research 
CONSIDER 
10 Laser treatment 
European Laser TrEAtment Dermatology 
registry 
LEAD 
11 Melanoma 
Developing a Core Outcome Set for Melanoma 
trials 
- 
12 Nail psoriasis 
Development of a Core Outcome Set in Nail 
Psoriasis 
- 
13 Pressure Ulcer The Outcomes for Pressure Ulcer Trials project OUTPUTs 
14 Rosacea Core Outcome Set for Rosacea IMPROVED 
15 
Vascular 
Malformations 
Development of a Core Outcome Set for 
Vascular Malformations  
OVAMA 
16 Vitiligo 
International Initiative for Outcomes (INFO) for 
vitiligo 
INFO vitiligo 
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